Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted therapeutics
PREDICT will define the next generation of predictive biomarkers through the integration of clinical trial design with functional cancer genomics to enable personalised medicine and the cost-effective delivery of beneficial cancer therapeutics.
Conference talks given: 35
Clinical samples collected (March 2014):
- A-PREDICT = 20 (expected by 06/2014 ~32)
- E-PREDICT = 29 (expected by 06/2014 = suspended to recruitment)
- NEO-RAD = 22 (expected by 06/2014 = 30)
RCC cell lines engineered: 18 (11 of established cell lines + 7 new from RCC-patient derived primary cell lines).